Toolkit Developed for Diagnosis and Management of Menopause
|
By LabMedica International staff writers Posted on 04 Aug 2014 |
A simple toolkit designed to help general practitioners (GP) diagnose and manage menopause is now available free of charge.
Created at Monash University (VIC, Australia), the "Practitioner Toolkit for Managing the Menopause" is the world’s first such kit, designed for GPs to use with women from the age of 40. The research team, led by Prof. Susan Davis, combined existing research on menopause, diagnostic algorithms, and extensive clinical experience to develop the diagnostic tool. It also helps the GP work through a patient’s medical history and risk factors to arrive at an optimal solution.
The toolkit fills the void of clear guidelines on diagnosis and management, equipping primary-care physicians, as well as nurses, with the fundamentals to provide more effective care for women. “There are many detailed guidelines available on menopause but the reality is that most GPs don’t have the time to work through a 40 page report [...] with a patient,” said Prof. Davis, “Based on feedback from patients and doctors we realized there’s widespread confusion." Also, "With many recent medical graduates receiving little training in this area, we realized there was a clear need for simple and practical guidelines,” she added.
Menopausal symptoms vary widely from none at all to debilitating, making a straightforward diagnosis difficult. "Every woman has her own individual experience of menopause and that sometimes makes it tricky to diagnose," said Prof. Davis. The kit includes a flow chart of standardized questions for doctors to ask in a routine consultation to help identify women who may be entering menopause. The kit also flags safety concerns, provides a list of hormone therapies approved by regulators in different countries, and lists non-hormonal therapies that have evidence to support their use. It also helps inform on benefits and risks of menopausal treatments. The kit is designed to work as well for a woman of age 41 in Madras as for one of age 48 in Manhattan, and the International Menopause Society is promoting its global use, stating that it is the first to present structured practical advice.
Jane Elliott, MD, said the toolkit was clear and accessible, making it ideal to use in GP consultations. Dr. Anna Fenton, a leading endocrinologist and president of the Australasian Menopause Society, also welcomed and recommended the toolkit: “In an area fraught with myths and misinformation, this toolkit provides concise and accurate information. The key messages are clear and the advice is practical and evidence-based,” said Dr. Fenton.
The paper on the kit was published online July 6, 2014, in the journal Climacteric.
Related Links:
Monash University
Menopause Toolkit for GPs
Created at Monash University (VIC, Australia), the "Practitioner Toolkit for Managing the Menopause" is the world’s first such kit, designed for GPs to use with women from the age of 40. The research team, led by Prof. Susan Davis, combined existing research on menopause, diagnostic algorithms, and extensive clinical experience to develop the diagnostic tool. It also helps the GP work through a patient’s medical history and risk factors to arrive at an optimal solution.
The toolkit fills the void of clear guidelines on diagnosis and management, equipping primary-care physicians, as well as nurses, with the fundamentals to provide more effective care for women. “There are many detailed guidelines available on menopause but the reality is that most GPs don’t have the time to work through a 40 page report [...] with a patient,” said Prof. Davis, “Based on feedback from patients and doctors we realized there’s widespread confusion." Also, "With many recent medical graduates receiving little training in this area, we realized there was a clear need for simple and practical guidelines,” she added.
Menopausal symptoms vary widely from none at all to debilitating, making a straightforward diagnosis difficult. "Every woman has her own individual experience of menopause and that sometimes makes it tricky to diagnose," said Prof. Davis. The kit includes a flow chart of standardized questions for doctors to ask in a routine consultation to help identify women who may be entering menopause. The kit also flags safety concerns, provides a list of hormone therapies approved by regulators in different countries, and lists non-hormonal therapies that have evidence to support their use. It also helps inform on benefits and risks of menopausal treatments. The kit is designed to work as well for a woman of age 41 in Madras as for one of age 48 in Manhattan, and the International Menopause Society is promoting its global use, stating that it is the first to present structured practical advice.
Jane Elliott, MD, said the toolkit was clear and accessible, making it ideal to use in GP consultations. Dr. Anna Fenton, a leading endocrinologist and president of the Australasian Menopause Society, also welcomed and recommended the toolkit: “In an area fraught with myths and misinformation, this toolkit provides concise and accurate information. The key messages are clear and the advice is practical and evidence-based,” said Dr. Fenton.
The paper on the kit was published online July 6, 2014, in the journal Climacteric.
Related Links:
Monash University
Menopause Toolkit for GPs
Latest Clinical Chem. News
- Blood Metabolite Test Detects Early Cognitive Decline
- AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
- CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
- Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
- Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
- New Tool Tracks Biomarker Changes to Predict Myeloma Progression
- New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
- First IVD Immunoassay to Detect Alzheimer’s Risk Gene Variant Receives CE Mark
- Routine Blood Markers Predict Heart Failure Risk in Prediabetes
- AI Model Enables Personalized Glucose Predictions for Type 1 Diabetes
- AI-Powered Blood Test Distinguishes Deadly Cardiac Events
- AI Sensor Detects Neurological Disorders Using Single Saliva Drop
- Blood Test Tracks Transplant Health Using Donor DNA
Channels
Molecular Diagnostics
view channel
cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample
Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more
Rapid Point-of-Care RT-PCR Test Differentiates Influenza A/B and SARS-CoV-2 in Minutes
Respiratory viruses such as influenza A/B and SARS‑CoV‑2 continue to burden urgent care and emergency settings, where rapid, reliable differentiation guides therapy and infection control.... Read moreHematology
view channel
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read more
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read more
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channelGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







